Christopher B. Jones, MD
Dr. Chris Jones is a medical oncologist and hematologist. He treats all types of cancer and blood disorders.
Patient Ratings
4.9 out of 5
Specialties & Conditions
- All Forms of Cancer
- Hematologic Cancers
- Hematologic Diseases
Research Areas
- Medical Oncology and Hematology
Special Interests
I am a clinical hematology/oncology physician. I see all types of hematologic disorders and every type of cancer. I am interested in cooperative group oncology clinical trials to promote best practice in oncology. I strive to perform top-notch care in a compassionate manner.
Education
Education
- 1997
- University of Miami School of Medicine, Miami, FL
Residency
- 2003
- Brooke Army Medical Center, Ft. Sam Houston, TX, Hematology/Oncology
- 2000
- Tripler Army Medical Center, Tripler, HI, Internal Medicine
Awards & Recognition
2021: 5280 Magazine Selection for Top Doctor in Denver
2019: Berris Award for Colorado Cancer Research Program Member displaying vision; leadership; commitment of time and resources; and for being a true cancer warrior
2005-2006: UTHSCA Outstanding Faculty Award for 3rd year Medical Student
2005: Bronze Star, Operation Iraqi Freedom II
2000: William J Uphouse Award for most compassionate physician
Board Certification
2003: Medical Oncology
2003: Hematology
2000: Internal Medicine
Professional Memberships
ASCO
American Society Hematology
Publications
Schwartz Garry H and Jones Christopher B. et al. A Phase I and Pharmacokinetic Study of Non-polyglutamatible Thymidylate Synthase Inhibitor ZD9331 and Docetaxel in Patients with Advanced Solid Malignancies. Investigational New Drugs 22: 437-448, 2004.
Mita AC, Hammond LA, Jones CB et al. Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12: 5207-5215, 2006.
R.F. Setlik, G. Preston, C.B Jones et al. A Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetic (PK) and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer. ASCO Clinical Proceedings, Abstract #2045, 2006
Shumway NM, Jones CB, and Terrazzino S. Randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. ASCO Clinical Proceedings, Abstract 9633, 2009
Teaching & Professional Positions
2021: Director, Brain Cancer Services, Ridley Tree Cancer Center
2021: Director, Leukemia Services, Ridley Tree Cancer Center
2015-2021: Director, NJH Extra-Thoracic Oncology Research Program
2015-2021: Lutheran Medical Center Breast Cancer Leadership Committee
2012-2015: Levine Cancer Institute, Leukemia Committee
2012-2015: Levine Cancer Institute, Upper/Lower GI Cancer Committee
2012-2015: Levine Cancer Institute, Genetic Committee
2008-2015: Levine Cancer Institute Breast Cancer Leadership Committee
2007-2008: Chief, Hematology/Oncology Services, Brooke Army Medical Center
2006-2008: Assistant Program Director, SAUSWEC Hematology/Oncology Fellowship
2005-2008: BAMC Breast Cancer Tumor Board Director
2004-2005: Chief Medical Services, 115th Field Hospital
2003-2008: BAMC General Surgery Tumor Board Oncology Director
Languages
English, Italian
The Patient metric-rating score is an average of all responses to
care provider related questions on our independent metric-rating
system, the Press Ganey Patient Satisfaction Survey. This survey is
about the patient care experience and does not address crucial
characteristics like medical decision-making, prescribing the best
therapy, and patient outcomes.